HCM
LSTA icon

Highbridge Capital Management’s Lisata Therapeutics LSTA Stock Holding History

Highbridge Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-149
Closed -$146K – 1284
2014
Q2 		$146K Buy
+149
New +$145K ﹤0.01% 990

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
TFO
Tarbox Family Office Newport Beach, California $616M AUM 18.34% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Highbridge Capital Management's LSTA Position: Q3 2014 in Review

Highbridge Capital Management sold out of Lisata Therapeutics (LSTA) in Q3 2014, closing a stake of 149 shares — an estimated $146K sold.

Highbridge Capital Management first reported a position in LSTA in Q2 2014 and held it in 1 quarter. The position peaked at $146K in Q2 2014. 50 funds tracked by Wall St. Rank hold LSTA as of Q3 2014.

  • Highbridge Capital Management reported no remaining Lisata Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Highbridge Capital Management sold 149 Lisata Therapeutics shares in Q3 2014, an estimated $146K.
  • Highbridge Capital Management first reported a position in Lisata Therapeutics in Q2 2014 and held it in 1 quarter.
  • Highbridge Capital Management's Lisata Therapeutics position peaked at $146K in Q2 2014.
  • 50 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2014.

Based on Highbridge Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.